TCA alleviated CFA-induced arthritis dependent on the interleukin cascade (IL-1β/IL-6/IL-23/IL-17) through promotion of the immunosuppressive and anti-inflammatory activities. This evidence concerns the gene IL17A and arthritic joint disease.